Literature DB >> 21210153

Renal manifestations of patients with MYH9-related disorders.

Kyoung Hee Han1, HyunKyung Lee, Hee Gyung Kang, Kyung Chul Moon, Joo Hoon Lee, Young Seo Park, Il Soo Ha, Hyo Seop Ahn, Yong Choi, Hae Il Cheong.   

Abstract

MYH9-related disorders are a group of autosomal, dominantly inherited disorders caused by mutations of the MYH9 gene, which encodes the non-muscle myosin heavy chain IIA (NMMHC-IIA). May-Hegglin anomaly and Sebastian, Fechtner, and Epstein syndromes belong to this group. Macrothrombocytopenia is a common characteristic associated with MYH9-related disorders, and basophilic cytoplasmic inclusion bodies in leukocytes (Döhle-like bodies), deafness, cataracts, and glomerulopathy are also found in some patients. In this study, renal manifestations of 7 unrelated Korean patients with MYH9-related disorders were analyzed. Of a total of 7 patients, 4 had disease-related family histories. One familial case had a mutation in the tail domain of NMMHC-IIA and showed milder renal involvement with preserved renal function by his 30s. Among the 3 familial cases without renal involvement, 2 had mutations in the tail domain of NMMHC-IIA and 1 had a mutation in the motor domain. The remaining 3 sporadic cases had severe renal involvement with rapid progression to end-stage renal disease and mutations located in the motor domain. In summary, mutations in the motor domain of NMMHC-IIA and negative family history were associated with severe renal involvement in patients with MYH9-related disorders. These results are in agreement with those of previous reports.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21210153     DOI: 10.1007/s00467-010-1735-3

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  32 in total

1.  Heavy chain myosin 9-related disease (MYH9 -RD): neutrophil inclusions of myosin-9 as a pathognomonic sign of the disorder.

Authors:  Anna Savoia; Daniela De Rocco; Emanuele Panza; Valeria Bozzi; Raffaella Scandellari; Giuseppe Loffredo; Andrew Mumford; Paula G Heller; Patrizia Noris; Marco R De Groot; Marisa Giani; Paolo Freddi; Francesca Scognamiglio; Silvia Riondino; Núria Pujol-Moix; Fabrizio Fabris; Marco Seri; Carlo L Balduini; Alessandro Pecci
Journal:  Thromb Haemost       Date:  2010-02-19       Impact factor: 5.249

2.  Germinal mosaicism in MYH9 disorders: a family with two affected siblings of normal parents.

Authors:  Shinji Kunishima; Kazutaka Takaki; Yoshimi Ito; Hidehiko Saito
Journal:  Br J Haematol       Date:  2009-02-04       Impact factor: 6.998

3.  May-Hegglin anomaly: morphologic and clinical manifestations.

Authors:  Hidehiko Saito; Shinji Kunishima
Journal:  Clin Adv Hematol Oncol       Date:  2009-02

4.  Nonmuscle myosin heavy chain IIA mutations define a spectrum of autosomal dominant macrothrombocytopenias: May-Hegglin anomaly and Fechtner, Sebastian, Epstein, and Alport-like syndromes.

Authors:  K E Heath; A Campos-Barros; A Toren; G Rozenfeld-Granot; L E Carlsson; J Savige; J C Denison; M C Gregory; J G White; D F Barker; A Greinacher; C J Epstein; M J Glucksman; J A Martignetti
Journal:  Am J Hum Genet       Date:  2001-10-04       Impact factor: 11.025

5.  First description of somatic mosaicism in MYH9 disorders.

Authors:  Shinji Kunishima; Tadashi Matsushita; Takao Yoshihara; Yoko Nakase; Kentaro Yokoi; Motohiro Hamaguchi; Hidehiko Saito
Journal:  Br J Haematol       Date:  2005-02       Impact factor: 6.998

6.  Immunofluorescence analysis of neutrophil nonmuscle myosin heavy chain-A in MYH9 disorders: association of subcellular localization with MYH9 mutations.

Authors:  Shinji Kunishima; Tadashi Matsushita; Tetsuhito Kojima; Masahiro Sako; Fumihiro Kimura; Eun-Kyeong Jo; Chikako Inoue; Tadashi Kamiya; Hidehiko Saito
Journal:  Lab Invest       Date:  2003-01       Impact factor: 5.662

7.  Historical hematology: May-Hegglin anomaly.

Authors:  Hidehiko Saito; Shinji Kunishima
Journal:  Am J Hematol       Date:  2008-04       Impact factor: 10.047

8.  A myosin family tree.

Authors:  T Hodge; M J Cope
Journal:  J Cell Sci       Date:  2000-10       Impact factor: 5.285

9.  Genetics, clinical and pathological features of glomerulonephritis associated with mutations of nonmuscle myosin IIA (Fechtner syndrome).

Authors:  Gian Marco Ghiggeri; Gianluca Caridi; Umberto Magrini; Adalberto Sessa; Anna Savoia; Marco Seri; Alessandro Pecci; Roberta Romagnoli; Simone Gangarossa; Patrizia Noris; Saverio Sartore; Vittorio Necchi; Roberto Ravazzolo; Carlo L Balduini
Journal:  Am J Kidney Dis       Date:  2003-01       Impact factor: 8.860

10.  Correlation between the clinical phenotype of MYH9-related disease and tissue distribution of class II nonmuscle myosin heavy chains.

Authors:  Valeria Marigo; Alessandra Nigro; Alessandro Pecci; Donatella Montanaro; Mariateresa Di Stazio; Carlo L Balduini; Anna Savoia
Journal:  Genomics       Date:  2004-06       Impact factor: 5.736

View more
  16 in total

1.  Effects of alcohol, lithium, and homocysteine on nonmuscle myosin-II in the mouse placenta and human trophoblasts.

Authors:  Mingda Han; Ana Luisa Neves; Maria Serrano; Pilar Brinez; James C Huhta; Ganesh Acharya; Kersti K Linask
Journal:  Am J Obstet Gynecol       Date:  2012-05-14       Impact factor: 8.661

Review 2.  Pathogenesis of glomerular haematuria.

Authors:  Claudia Yuste; Eduardo Gutierrez; Angel Manuel Sevillano; Alfonso Rubio-Navarro; Juan Manuel Amaro-Villalobos; Alberto Ortiz; Jesus Egido; Manuel Praga; Juan Antonio Moreno
Journal:  World J Nephrol       Date:  2015-05-06

Review 3.  MYH9: Structure, functions and role of non-muscle myosin IIA in human disease.

Authors:  Alessandro Pecci; Xuefei Ma; Anna Savoia; Robert S Adelstein
Journal:  Gene       Date:  2018-04-19       Impact factor: 3.688

Review 4.  Haematuria as a risk factor for chronic kidney disease progression in glomerular diseases: A review.

Authors:  Juan Antonio Moreno; Claudia Yuste; Eduardo Gutiérrez; Ángel M Sevillano; Alfonso Rubio-Navarro; Juan Manuel Amaro-Villalobos; Manuel Praga; Jesús Egido
Journal:  Pediatr Nephrol       Date:  2015-05-17       Impact factor: 3.714

5.  MYH9-related disease: a novel prognostic model to predict the clinical evolution of the disease based on genotype-phenotype correlations.

Authors:  Alessandro Pecci; Catherine Klersy; Paolo Gresele; Kieran J D Lee; Daniela De Rocco; Valeria Bozzi; Giovanna Russo; Paula G Heller; Giuseppe Loffredo; Matthias Ballmaier; Fabrizio Fabris; Eloise Beggiato; Walter H A Kahr; Nuria Pujol-Moix; Helen Platokouki; Christel Van Geet; Patrizia Noris; Preethi Yerram; Cedric Hermans; Bernhard Gerber; Marina Economou; Marco De Groot; Barbara Zieger; Erica De Candia; Vincenzo Fraticelli; Rogier Kersseboom; Giorgina B Piccoli; Stefanie Zimmermann; Tiziana Fierro; Ana C Glembotsky; Fabrizio Vianello; Carlo Zaninetti; Elena Nicchia; Christiane Güthner; Carlo Baronci; Marco Seri; Peter J Knight; Carlo L Balduini; Anna Savoia
Journal:  Hum Mutat       Date:  2013-12-12       Impact factor: 4.878

6.  MYH9 nephropathy.

Authors:  Taehoon Oh; Hyun Jung Seo; Kyu Taek Lee; Han Jo Kim; Hwi Jun Kim; Ji-Hye Lee; Hae Il Cheong; Eun Young Lee
Journal:  Kidney Res Clin Pract       Date:  2014-11-28

7.  Isolated microscopic haematuria of glomerular origin: clinical significance and diagnosis in the 21st century.

Authors:  Melanie My Chan; Daniel P Gale
Journal:  Clin Med (Lond)       Date:  2015-12       Impact factor: 2.659

Review 8.  How benign is hematuria? Using genetics to predict prognosis.

Authors:  Daniel P Gale
Journal:  Pediatr Nephrol       Date:  2013-01-17       Impact factor: 3.714

Review 9.  Myosinopathies: pathology and mechanisms.

Authors:  Homa Tajsharghi; Anders Oldfors
Journal:  Acta Neuropathol       Date:  2012-08-05       Impact factor: 17.088

10.  MYH9-related disease: five novel mutations expanding the spectrum of causative mutations and confirming genotype/phenotype correlations.

Authors:  Daniela De Rocco; Barbara Zieger; Helen Platokouki; Paula G Heller; Annalisa Pastore; Roberta Bottega; Patrizia Noris; Serena Barozzi; Ana C Glembotsky; Helen Pergantou; Carlo L Balduini; Anna Savoia; Alessandro Pecci
Journal:  Eur J Med Genet       Date:  2012-10-30       Impact factor: 2.708

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.